StageZero Life Sciences, Ltd Announces Results of Special Meeting

Rhea-AI Summary

StageZero Life Sciences announced that shareholders approved the issuance of 8,000,000 common shares to Health Clinics Limited. This issuance is part of the acquisition of Clinic Operations Limited and is contingent on achieving specific milestones. At the special meeting, 90.005% of the shares voted were in favor of this resolution. StageZero focuses on cancer detection and management through advanced diagnostics, including its Aristotle mRNA multi-cancer panel, validated with over 9,000 patients.

Positive

• Shareholder approval for issuance of 8,000,000 shares, indicating strong investor support.
• Acquisition of Clinic Operations Limited could enhance operational capabilities.
• Aristotle test validated in over 9,000 patients, ensuring credibility and effectiveness.

Negative

• None.

TORONTO, ON and RICHMOND, VA / ACCESSWIRE / December 10, 2021 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, is pleased to report that shareholders today approved at a special meeting the issuance of 8,000,000 common shares of the Company to Health Clinics Limited. The share issuance is in connection with the Company's prior acquisition of all of the issued and outstanding shares of Clinic Operations Limited, a wholly-owned subsidiary of Health Clinics Limited ("Acquisition"). The issuance of these shares is contingent upon the achievement of certain milestones.

Of the Common Shares voted at the Meeting, 90.005% of the Common Shares were voted in favour of the Resolution.

Further details of the business considered at the meeting may be found in the Company's management information circular dated October 21, 2021 (the "Circular"). and posted on the System for Electronic Data Analysis and Retrieval (SEDAR) at www.sedar.com. Voting results are released in accordance with Toronto Stock Exchange ("TSX") requirements.

About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and a unique telehealth program that provides clinical interventions to help patients reduce the risk of developing late-stage disease (AVRT™).

The Company's next generation test, Aristotle®, is the first-ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.

Aristotle®, as well as additional cancer diagnostics (ColonSentry®, BreastSentry™, and the Prostate Health Index) are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).

StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.

Matthew Pietras
CFO & COO

Company Contacts:
Rebecca Greco
Investor Relations
rgreco@stagezerols.com
Tel: 1-855-420-7140 Ext. 1838

SOURCE: StageZero Life Sciences Ltd

View source version on accesswire.com:
https://www.accesswire.com/676944/StageZero-Life-Sciences-Ltd-Announces-Results-of-Special-Meeting

FAQ

What was approved at the StageZero Life Sciences special meeting on December 10, 2021?

Shareholders approved the issuance of 8,000,000 common shares to Health Clinics Limited.

What percentage of shares voted in favor of the resolution during the meeting?

90.005% of the common shares voted were in favor of the resolution.

What is the significance of the share issuance for StageZero Life Sciences?

The share issuance is related to the acquisition of Clinic Operations Limited, potentially enhancing the company's operations.

What is the Aristotle test developed by StageZero Life Sciences?

The Aristotle test is the first mRNA multi-cancer panel that screens for multiple cancers from a single blood sample.

What stock exchanges does StageZero Life Sciences trade on?

StageZero Life Sciences trades on the TSX under SZLS and on the OTCQB under SZLSF.